Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 12/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | CCNK | O75909 | 1/20 | 0.55 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CCR7 | P32248 | 2/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | TGM1 | P22735 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25079489 | 0.92 | CCR6 (0.52) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL25079882 | 0.91 | CCR6 (0.60) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL25079503 | 0.90 | CCR6 (0.61) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL25079459 | 0.89 | CCR6 (0.68) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL30284786 | 0.89 | CCR6 (0.68) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL26460934 | 0.89 | CCNA2 (0.63) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL25079494 | 0.87 | SYK (0.48) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL25079824 | 0.86 | CCR6 (0.64) | CCR6CCNA2CDK2CCNKCDK12 | |
| Hydrochloric Acid SCHEMBL30284807 | 0.86 | CCR6 (0.63) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL30284788 | 0.86 | CCR6 (0.63) | CCR6CCNA2CDK2CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387965-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023023534-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CCR6, CCR1, CCR3 | CCR6 1/4885CCNA2 2911/4885CDK2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.